# TAS102 in Combination With NAL-IRI in Advanced GI Cancers

> **NCT03368963** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Emory University** · enrollment: 64 (estimated)

## Conditions studied

- Colorectal Adenocarcinoma
- Gastric Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- Non-Resectable Cholangiocarcinoma
- Stage IV Colorectal Cancer
- Stage IV Gastric Cancer
- Stage IV Pancreatic Cancer
- Stage IVA Colorectal Cancer
- Stage IVB Colorectal Cancer
- Stage III Colorectal Cancer
- Stage III Gastric Cancer
- Stage III Pancreatic Cancer
- Unresectable Digestive System Adenocarcinoma
- Unresectable Pancreatic Carcinoma

## Interventions

- **DRUG:** Nanoliposomal Irinotecan
- **DRUG:** Trifluridine and Tipiracil Hydrochloride

## Key facts

- **NCT ID:** NCT03368963
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-30
- **Primary completion:** 2025-06-28
- **Final completion:** 2025-11-28
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03368963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03368963, "TAS102 in Combination With NAL-IRI in Advanced GI Cancers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03368963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*